We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+12.89%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$992M
AUM Growth
+$216M
Cap. Flow
+$197M
Cap. Flow %
19.86%
Top 10 Hldgs %
62.98%
Holding
46
New
6
Increased
7
Reduced
8
Closed
2

Top Buys

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$113M
2
SVA
Sinovac Biotech, Ltd
SVA
+$42.6M
3
AMRS
Amyris Inc.
AMRS
+$20.2M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$16.3M
5
ACER
Acer Therapeutics Inc
ACER
+$15.2M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$17.4M
2
RGNX icon
Regenxbio
RGNX
+$5.91M
3
SBBP
Strongbridge Biopharma plc.
SBBP
+$5.12M
4
CDXS icon
Codexis
CDXS
+$4.93M
5
QTTB icon
Q32 Bio
QTTB
+$4.72M

Sector Composition

Rank Sector Weight
1 Healthcare 95.48%
2 Materials 4.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
26
Zymeworks
ZYME
$1.67B
$9.74M 0.98%
620,134
– –
SLNO
27
DELISTED
Soleno Therapeutics
SLNO
$9.42M 0.95%
290,646
– –
DCPH
28
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$8.23M 0.83%
212,648
-40,294
-16% -$1.49M
AUPH icon
29
Aurinia Pharmaceuticals
AUPH
$1.93B
$8.06M 0.81%
1,213,290
– –
KNSA icon
30
Kiniksa Pharmaceuticals
KNSA
$6.1B
$6.75M 0.68%
264,878
+78,805
+42% +$1.53M
GNCA
31
DELISTED
Genocea Biosciences, Inc.
GNCA
$6.38M 0.64%
1,022,500
– –
ZGNX
32
DELISTED
Zogenix, Inc.
ZGNX
$5.21M 0.52%
105,000
– –
ARVN icon
33
Arvinas
ARVN
$536M
$5.06M 0.51%
+300,000
New +$4.94M
ZLAB icon
34
Zai Lab
ZLAB
$2.06B
$4.5M 0.45%
231,010
– –
SBBP
35
DELISTED
Strongbridge Biopharma plc.
SBBP
$4.45M 0.45%
918,132
-1,000,000
-52% -$5.12M
SRRA
36
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.14M 0.42%
60,957
– –
TRVN
37
DELISTED
Trevena, Inc.
TRVN
$3.66M 0.37%
2,765
– –
TMBR
38
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$3.06M 0.31%
1,075
– –
FOMX
39
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.45M 0.25%
427,500
-427,500
-50% -$2.45M
AKTX
40
Akari Therapeutics
AKTX
$14M
$885K 0.09%
432
– –
AGRX
41
DELISTED
Agile Therapeutics
AGRX
$555K 0.06%
757
– –
VIRX
42
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$391K 0.04%
5,585
– –
ONCT
43
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$165K 0.02%
+750
New +$1.8M
SLNOW
44
DELISTED
Soleno Therapeutics, Inc. Series A Warrant
SLNOW
$23K ﹤0.01%
188,772
– –
MDGL icon
45
Madrigal Pharmaceuticals
MDGL
$11.4B
– –
-62,220
Closed -$17.4M
RGNX icon
46
Regenxbio
RGNX
$648M
– –
-82,403
Closed -$5.91M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Vivo Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Vivo Capital held 46 positions worth $992M, up 28% from $776M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Vivo Capital deployed $197M of net new capital in Q3 2018, opening 6 new positions and adding to 7 existing holdings. Its largest new stake was Crinetics Pharmaceuticals: 3,792,169 shares worth $109M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Strongbridge Biopharma plc., an estimated $5.12M trimmed.

  • Vivo Capital's largest Q3 2018 buy was Crinetics Pharmaceuticals: 3,792,169 shares worth $109M.
  • Vivo Capital added most to Amyris Inc. in Q3 2018, an estimated $20.2M increase.
  • Vivo Capital's biggest Q3 2018 reduction was Strongbridge Biopharma plc., cutting an estimated $5.12M.
  • Vivo Capital fully exited Madrigal Pharmaceuticals in Q3 2018, selling an estimated $17.4M.
  • Vivo Capital's ten largest holdings make up 63% of its $992M portfolio in Q3 2018.
  • Vivo Capital opened 6 new positions and closed 2 in Q3 2018.
  • Vivo Capital's portfolio value rose 28% quarter-over-quarter to $992M.

Based on Vivo Capital's 13F filing for Q3 2018, filed 13 Nov 2018.